Cytek Biosciences, Inc.
Informe acción DB:8EQ
Capitalización de mercado: €858.8m
Salud financiera de hoja de balance de Cytek Biosciences
Salud financiera controles de criterios 5/6 Cytek Biosciences tiene un patrimonio de los accionistas total de $385.5M y una deuda total de $3.2M, lo que sitúa su ratio deuda-patrimonio en 0.8%. Sus activos y pasivos totales son $491.2M y $105.8M respectivamente.
Información clave
0.8%
Ratio deuda-patrimonio
Ratio de cobertura de intereses n/a Efectivo US$277.78m Patrimonio US$385.46m Total pasivo US$105.76m Activos totales US$491.23m
Actualizaciones recientes sobre salud financiera Cytek Biosciences, Inc. announced delayed annual 10-K filing Mar 03
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 15
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 14
Mostrar todas las actualizaciones
Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs System Nov 08
New major risk - Share price stability Nov 08
Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023) Nov 07
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 06
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12
Second quarter 2024 earnings released: US$0.079 loss per share (vs US$0.032 loss in 2Q 2023) Aug 07 Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024 Aug 07
Cytek Biosciences, Inc. Automates Panel Design with New Intelligent Algorithm Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. Jun 08
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024 May 10
Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024 May 01
Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024 Apr 28 Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics Cytek Biosciences, Inc. announced delayed annual 10-K filing Mar 03
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Mar 01
Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry Dec 21
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 15
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 14
Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.012 profit in 3Q 2022) Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Nov 08
Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
New minor risk - Share price stability Oct 06
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services Aug 29
Second quarter 2023 earnings released: US$0.032 loss per share (vs US$0.004 loss in 2Q 2022) Aug 09
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. May 20
First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.015 loss in 1Q 2022) May 11
Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023 May 10
Full year 2022 earnings released: EPS: US$0.018 (vs US$0.001 in FY 2021) Mar 02
Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million. Feb 14
Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Cytek Biosciences, Inc. Introduces Cytek Cloud Nov 16
Third quarter 2022 earnings released: EPS: US$0.012 (vs US$0.003 in 3Q 2021) Nov 11
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022 Nov 10
Cytek Biosciences, Inc. Names Chris Williams Chief Operating Officer Nov 01
Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
Second quarter 2022 earnings released Aug 12
Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 11
Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index Jun 26
Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022 Jun 24
Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I Director Jun 07
First quarter 2022 earnings released May 13
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022 May 12
Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 28
Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Feb 24
Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 12
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($390.2M) de 8EQ superan a sus pasivos a corto plazo ($62.8M).
Pasivo a largo plazo: Los activos a corto plazo de 8EQ ($390.2M) superan a sus pasivos a largo plazo ($43.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 8EQ tiene más efectivo que su deuda total.
Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de 8EQ se ha reducido en los últimos 5 años.
Análisis de cash runway En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable 8EQ tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre .
Pronóstico de cash runway: 8EQ no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 8.5% al año.
Descubre empresas con salud financiera Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}